MedTrace Logo

Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02257216 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2018-04-11

No results posted yet for this study

Summary

The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.

Conditions

  • Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

OTHER

Vayarin®

Medical Food

OTHER

Placebo

Cellulose

Sponsors & Collaborators

  • Enzymotec

    lead INDUSTRY

Principal Investigators

  • Lenard A Adler, M.D · NYU Langone Health

  • Michael Banov, M.D · Northwest Behavioral Research Center

  • Michael R Liebowitz, M.D · The Medical Research Network, LLC

  • David S Krakow, M.D · Bioscience Research, LLC

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-05-31
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02257216 on ClinicalTrials.gov